Skip to Content
Current OncologyCurrent Oncology
  • Review
  • Open Access

1 December 2007

8 Pages

Cancer Therapy Disparity: Unequal Access to Breast Cancer Therapeutics and Drug Funding in Canada

,
and
1
Division of Medical Oncology, Toronto–Sunnybrook Regional Cancer Centre, Sunnybrook and Women’s College Health Sciences Centre, Toronto, ON, Canada
2
The Oncology Group, William Osler Health Centre, Brampton, ON, Canada
3
Cross Cancer Institute, Edmonton, AB, Canada
*
Author to whom correspondence should be addressed.

Abstract

Adjuvant therapy has made a significant contribution in reducing breast cancer–specific mortality. Standard chemotherapeutics and tamoxifen have been the mainstay treatment for years, but recent clinical evidence supports the use of novel small-molecule therapy and aromatase inhibitor therapy in selected settings, challenging not only the traditional paradigm of breast cancer treatment, but also provincial funding of oncologic care across Canada. The disparity in access to aromatase inhibitor therapy for postmenopausal women with early-stage hormone-sensitive breast cancer across Canada is highlighted as an example.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.